<DOC>
	<DOCNO>NCT00413192</DOCNO>
	<brief_summary>The purpose study evaluate therapeutic activity safety E7389 patient advanced/metastatic soft tissue sarcoma fail standard chemotherapy .</brief_summary>
	<brief_title>E7389 Administered IV Bolus Infusion Day 1 Day 8 Every 3 Weeks Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>1 . Histologically proven advance and/or metastatic malignant soft tissue sarcoma high intermediate grade , one follow histology ( World Health Organization ( WHO ) classification 2002 ) : Leiomyosarcoma Adipocytic ( liposarcoma dedifferentiate , myxoid/round cell , pleomorphic , mixedtype otherwise specify ) Synovial sarcoma Other type sarcoma , include : Fibroblastic ( adult fibrosarcoma , myxofibrosarcoma , sclerosing epithelioid fibrosarcoma ) . Socalled fibrohistiocytic ( pleomorphic Malignant Fibrous Histiocytoma ( MFH ) , giant cell `` MFH '' , inflammatory `` MFH '' ) Malignant glomus tumor . Skeletal muscle ( rhabdomyosarcoma , alveolar pleomorphic ) exclude embryonal rhabdomyosarcoma . Vascular ( epithelioid haemangioendothelioma , angiosarcoma ) . Uncertain differentiation ( synovial , epithelioid , alveolar soft part , clear cell , desmoplastic small round cell , extrarenal rhabdoid , malignant mesenchymoma , perivascular epithelioid cell tumor ( PEComa ) , intimal sarcoma ) exclude chondrosarcoma , Ewing tumor / Primitive neuroectodermal tumor ( PNET ) Malignant peripheral nerve sheath tumor . Malignant solitary fibrous tumor . Undifferentiated soft tissue sarcoma otherwise specify . Other type sarcoma ( list eligible ) , approve Study Coordinator ( write email approval need prior registration ) . The following tumor type eligible : Embryonal rhabdomyosarcoma Chondrosarcoma Osteosarcoma Ewing tumor / PNET Gastrointestinal stromal tumor ( GIST ) Dermatofibrosarcoma protuberans Inflammatory myofibroblastic sarcoma Neuroblastoma Malignant mesothelioma Mixed mesodermal tumor uterus 2 . Formalin fix paraffin embed tumor block representative H/E ( hematoxylin/eosin ) slide must available histological central review . Histological central review require treatment start mandatory within 10 day registration . Local histopathological diagnosis accept entry study . 3 . Relapsed , refractory and/or metastatic disease incurable surgery radiotherapy . 4 . Evidence objective progression within last 6 month ( RECIST ) document measurement disease , i.e . appearance new lesion , increase 20 % sum diameter measurable lesion , progression non measurable lesion confirm external review , without specific treatment since objective documentation progression . 5 . Presence measurable disease , define RECIST . 6 . Patients must receive one combination two single agent chemotherapy regimens advanced disease ; ( neo ) adjuvant therapy count towards requirement . 7 . No major surgery , hormonal therapy ( replacement ) , chemotherapy radiotherapy , immunotherapy investigational agent within last 28 day and/or recover prior therapy within last 28 day . Use erythropoietin consider supportive care permit . 8 . Absence brain subdural metastasis , unless patient complete local therapy discontinue use corticosteroid indication least 4 week start treatment E7389 . Any sign ( e.g. , radiologic ) and/or symptom brain metastasis must stable least 4 week . 9 . Absence preexist neuropathy &gt; Grade 2 10 . At least 18 year age . 11. WHO performance status 0 1 . 12 . Adequate bone marrow function ( absolute neutrophil count &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L ) 13 . Adequate hepatic function ( bilirubin &lt; 1.5 mg/mL 25 µmol/L , SGOT/AST SGPT/ALT &lt; = 3 x UNL &lt; 5 x UNL patient liver metastasis ) . 14 . Adequate renal function : serum creatinine &lt; 2.0 mg/dl 177 µmol/l calculate ( Cockcroft Gault formula ) creatinine clearance &gt; 40 ml/min . 15 . Women either childbearing potential ( hysterectomy , bilateral oophorectomy bilateral tubal ligation , postmenopausal total cessation menses &gt; 1 year ) , pregnant ( negative serum pregnancy test entry ) , lactate , agree use contraceptive method ( documented failure rate &lt; 1 % , vasectomized partner sterile prior trial entry sole sexual partner doublebarrier contraception ) treatment period 3 month end treatment . Sexually active male participant must use barrier method contraception . 16 . Before patient registration/randomization , write informed consent must give accord International Conference Harmonization/Good Clinical Practice ( ICH/GCP ) , national/local regulation . 1 . Prior history malignancy sarcoma ( except basal cell squamous cell carcinoma skin , carcinoma situ cervix breast , patient free malignancy &gt; 3 year ) . 2 . Significant cardiovascular impairment ( history congestive heart failure &gt; New York Heart Association ( NYHA ) grade II , unstable angina myocardial infarction within past six month , serious cardiac arrhythmia ) . 3 . Patients receive anticoagulant therapy warfarin related compound , line patency , change heparinbased therapy , eligible . If patient continue minidose warfarin , prothrombin time ( PT ) / international normalize ratio ( INR ) must closely monitor . 4 . Severe/uncontrolled intercurrent illness/infection . 5 . Patients know hypersensitivity halichondrin B and/or halichondrin B chemical derivative . 6 . Patients participate prior E7389 clinical trial . 7 . Patients without freedom ( law administrative decision ) , hospitalize without consent ( mental disability , upon legal request ) , admit medical social establishment reason clinical research , psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule ; condition assess patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>